ArticleBMC infectious diseases2024

Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain.

Ruth Gil-Prieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.